Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Venetoclax combined with three-day multi-frequency Decitabine (DEC3-VEN) in the treatment of adult patients with de novo Acute Myeloid Leukemia：updated results of a phase II trial

View Full Paper
Ask AI
Bookmark
Share

Authors

ZZZeping ZhouXLXinxiao LuLYLinyu Yuan

Discussion

Loading...

Member takes

Overview

Phase II trial shows improved overall response rates in adult patients with Acute Myeloid Leukemia, suggesting significant benefits of DEC3-VEN therapy.

Key Points

  • Overall response rate (ORR) reached 90.5% after the induction therapy with DEC3-VEN in adults with newly diagnosed AML.
  • Complete remission with incomplete recovery rate was 85.2%, while minimal residual disease negativity was noted in 80.2% of responders.
  • Single-arm prospective trial evaluated efficacy of venetoclax and decitabine in treating AML patients in China.
  • This regimen could be a promising option for AML induction therapy, highlighting the need for further comparative studies.

Cite This Study

Zhou et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e3bdhttps://doi.org/10.1182/blood-2025-1675
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) VS venetoclax combined with azacitidine in elderly patients with Acute Myeloid Leukemia：a phase III, prospective, multicenter, randomized controlled trial2025
  2. 2Predictive significance of early bone marrow MRD response assessment in Acute Myeloid Leukemia patients treated with venetoclax plus decitabine induction therapy: Real-world data from India2025
  3. 3Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) as induction treatment in newly diagnosed Acute Myeloid Leukemia with TP53-mutantion2025 · 1 citations
  4. 4Low-dose 10-day decitabine plus venetoclax induced rapid MRD negativity and durable remission in de novo AML and high-risk MDS2025
  5. 5Reduced intensive chemotherapy combined with venetoclax in adult patients with Acute Myeloid Leukemia: A retrospective single-center analysis2025